Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB9741 in Healthy Participants and Moderate-to-Severe Atopic Dermatitis
NCT04643457Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of galvokimig in atopic dermatitis (AD), sponsored by UCB. Started Nov 2020; status: completed.
02
Drugs
galvokimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04643457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643457.